PPARA and cystic fibrosis: Therefore, combined with the analysis of the two docking results, we predict that 3′-O-methyl-4-O-(n′′-O-galloyl-β-d-xylopyranosyl) ellagic acid (n = 2, 3 or 4) and 4-O-(3′′,4′′-O-digalloyl-α-l-rhamnosyl) ellagic acid may inhibit the PPAR signaling pathway by inhibiting the PPARα protein and FABP protein, which may be the toxic components of CF.